Sort
4,870 grants matching “glp 1”
Phase one clinical trial of a novel small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein- Barr positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic correlative studies
$629,493A. Dimitrios Colevas · Stanford University · R01 · FY2019 · CA
TARGETING MASH WITH NOVEL SMALL MOLECULE TXNIP INHIBITOR
$629,249Anath Shalev · University Of Alabama At Birmingham · R01 · FY2024 · DK
Restoration of Skin Structure and Function Post-Wounding
$629,215Gautam Sudhir Ghatnekar · Xequel Bio, Inc. · R42 · FY2009 · AR
EXPRESSION OF GPCRS FOR STRUCTURE DETERMINATION
$628,625Three-Dimensional Pharmaceuticals, Inc. · R44 · FY2001 · GM
Pathophysiological mechanisms in the brain's endogenous glucagon-like peptide 1 system mediated by obesogenic diets
$628,341James Andrew Hardaway · University Of Alabama At Birmingham · R01 · FY2025 · DK
Depot intra-articular fluticasone for the treatment of arthritis
$628,279Thomas J. Smith · Auritec Pharmaceuticals, Inc. · R44 · FY2014 · AR
Black Bear Parathyroid Hormone as an Anabolic Agent for Bone
$628,278Seth W Donahue · Proteos, Inc. · R42 · FY2010 · DK
Engineered Glucose Metabolism in Insulin Secreting Cells
$627,997Christopher B Newgard · Duke University · R01 · FY2025 · DK
Core D: Biomarkers, Genomics & Epigenomics Core
$627,534Isaac Kirubakaran Sundar · Roswell Park Cancer Institute Corp · U54 · FY2022 · CA
Human Antibody Therapeutics Against Anthrax
$627,428Alexion Pharmaceuticals, Inc. · U01 · FY2005 · AI
Core D: Biomarkers, Genomics & Epigenomics Core
$627,186Isaac Kirubakaran Sundar · Roswell Park Cancer Institute Corp · U54 · FY2020 · CA
Core D: Biomarkers, Genomics & Epigenomics Core
$626,991Isaac Kirubakaran Sundar · Roswell Park Cancer Institute Corp · U54 · FY2021 · CA
Iron Chelators Predicated on Desferrithiocin
$625,942Raymond J Bergeron · University Of Florida · R37 · FY2012 · DK
Novel Extracorporeal Device 'Amytrapper' To Remove Beta Amyloid In Alzheimer'sDisease
$625,405Pazhani Sundaram · Recombinant Technologies, Llc · R44 · FY2025 · AG
Development of a novel dual HIF-α inhibitor and inducer of ferroptosis for kidney cancer
$625,000Robert Lippert · Kuda Therapeutics, Inc. · R44 · FY2023 · CA
Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)
$625,000Lorenzo Leggio · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2013 · AA
Iron Chelators Predicated on Desferrithiocin
$624,628Raymond J Bergeron · University Of Florida · R37 · FY2011 · DK
iOP-Connect System for Long-Term Continuous Monitoring of Glaucoma Therapy by means of an Implantable Autonomous Intraocular Pressure Sensor
$624,000Kevin Douglas Berg · Injectsense, Inc. · R44 · FY2023 · EY
Phase one clinical trial of a novel small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein- Barr positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic correlative studies
$623,900A. Dimitrios Colevas · Stanford University · R01 · FY2021 · CA
Research Project I: AAV-CRISPR to Treat Huntington's Disease
$623,889Krystof S Bankiewicz · University Of California Berkeley · U19 · FY2025 · NS
Resource Core II: In Vivo Core
$623,888Piotr Hadaczek · University Of California Berkeley · U19 · FY2025 · NS
Second generation GLP-1 agonists without nausea/emesis side effects
$623,536Matthew R Hayes · University Of Pennsylvania · R01 · FY2021 · DK
Biobehavioral Studies of Obesity, Weight loss and Recidivism
$623,171Monica Skarulis · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2015 · DK
Treatment of Muscular Dystrophy-associated Dilated Cardiomyopathy with P-188
$622,877Bruce E. Markham · Phrixus Pharmaceuticals, Inc. · R43 · FY2012 · HL
Pharmacogenetic discovery in the GRADE comparative effectiveness type 2 diabetes clinical trial
$622,623Jose Carlos Florez · Massachusetts General Hospital · R01 · FY2024 · DK